Research ArticleArticle
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells
Sean A. Misek, Patrick A. Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I. Doseff, Bin Chen, Kathleen A. Gallo and Richard R. Neubig
Molecular Pharmacology January 2022, 101 (1) 1-12; DOI: https://doi.org/10.1124/molpharm.121.000331
Sean A. Misek
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Patrick A. Newbury
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Evgenii Chekalin
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Shreya Paithankar
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Andrea I. Doseff
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Bin Chen
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Kathleen A. Gallo
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan
Richard R. Neubig
Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Ibrutinib Resensitizes BRAFi-Resistant Melanoma
Sean A. Misek, Patrick A. Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I. Doseff, Bin Chen, Kathleen A. Gallo and Richard R. Neubig
Molecular Pharmacology January 1, 2022, 101 (1) 1-12; DOI: https://doi.org/10.1124/molpharm.121.000331
Research ArticleArticle
Ibrutinib Resensitizes BRAFi-Resistant Melanoma
Sean A. Misek, Patrick A. Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I. Doseff, Bin Chen, Kathleen A. Gallo and Richard R. Neubig
Molecular Pharmacology January 1, 2022, 101 (1) 1-12; DOI: https://doi.org/10.1124/molpharm.121.000331
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement